BioLineRx (BLRX) Competitors $3.70 -0.04 (-1.07%) Closing price 04:00 PM EasternExtended Trading$3.74 +0.03 (+0.95%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLRX vs. ANL, GANX, CVM, HOWL, IZTC, ADVM, INKT, UNCY, DRRX, and KALAShould you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Adlai Nortye (ANL), Gain Therapeutics (GANX), CEL-SCI (CVM), Werewolf Therapeutics (HOWL), Invizyne Technologies (IZTC), Adverum Biotechnologies (ADVM), MiNK Therapeutics (INKT), Unicycive Therapeutics (UNCY), DURECT (DRRX), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry. BioLineRx vs. Its Competitors Adlai Nortye Gain Therapeutics CEL-SCI Werewolf Therapeutics Invizyne Technologies Adverum Biotechnologies MiNK Therapeutics Unicycive Therapeutics DURECT KALA BIO BioLineRx (NASDAQ:BLRX) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Do insiders and institutionals have more ownership in BLRX or ANL? 1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is BLRX or ANL more profitable? Adlai Nortye has a net margin of 0.00% compared to BioLineRx's net margin of -45.34%. Adlai Nortye's return on equity of 0.00% beat BioLineRx's return on equity.Company Net Margins Return on Equity Return on Assets BioLineRx-45.34% -49.74% -17.54% Adlai Nortye N/A N/A N/A Do analysts recommend BLRX or ANL? BioLineRx presently has a consensus target price of $26.00, indicating a potential upside of 602.70%. Adlai Nortye has a consensus target price of $9.00, indicating a potential upside of 430.97%. Given BioLineRx's stronger consensus rating and higher possible upside, analysts clearly believe BioLineRx is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor BLRX or ANL? In the previous week, BioLineRx had 10 more articles in the media than Adlai Nortye. MarketBeat recorded 12 mentions for BioLineRx and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.31 beat BioLineRx's score of 0.04 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adlai Nortye 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, BLRX or ANL? BioLineRx has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -0.95, indicating that its share price is 195% less volatile than the S&P 500. Which has better earnings and valuation, BLRX or ANL? BioLineRx has higher revenue and earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLineRx$28.94M0.54-$9.22M-$8.80-0.42Adlai NortyeN/AN/A-$51.87MN/AN/A SummaryBioLineRx beats Adlai Nortye on 9 of the 14 factors compared between the two stocks. Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLRX vs. The Competition Export to ExcelMetricBioLineRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.76M$2.56B$5.75B$9.60BDividend YieldN/A1.68%4.54%4.09%P/E Ratio-0.4222.0130.4025.01Price / Sales0.54551.57415.24176.62Price / CashN/A176.7537.3459.16Price / Book0.795.288.956.28Net Income-$9.22M$31.83M$3.26B$265.47M7 Day Performance-6.09%-0.52%-0.19%-2.06%1 Month Performance-17.23%2.83%3.83%0.32%1 Year Performance-87.59%7.74%28.78%20.75% BioLineRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLRXBioLineRx3.3022 of 5 stars$3.70-1.1%$26.00+602.7%-88.2%$15.76M$28.94M-0.4240Earnings ReportAnalyst RevisionGap UpANLAdlai Nortye1.3666 of 5 stars$1.77+4.8%$9.00+408.2%-44.4%$62.36M$5M0.00127News CoverageShort Interest ↑Gap UpGANXGain Therapeutics2.2385 of 5 stars$1.77+2.3%$7.80+340.7%+15.8%$62.19M$50K-2.8120High Trading VolumeCVMCEL-SCI1.5795 of 5 stars$8.92+2.5%N/A-75.1%$61.39MN/A-18.5843Short Interest ↓HOWLWerewolf Therapeutics3.41 of 5 stars$1.33flat$8.33+526.6%-41.5%$60.82M$1.88M-0.8140News CoverageEarnings ReportAnalyst RevisionIZTCInvizyne TechnologiesN/A$9.70-2.9%N/AN/A$60.64MN/A0.0029News CoverageADVMAdverum Biotechnologies3.8807 of 5 stars$2.93+2.4%$19.75+574.1%-60.8%$60.01M$1M-0.37190News CoverageAnalyst RevisionINKTMiNK Therapeutics2.9406 of 5 stars$14.62-1.9%$37.50+156.5%+75.2%$59.43MN/A0.0030Earnings ReportAnalyst DowngradeUNCYUnicycive Therapeutics2.6293 of 5 stars$4.08-13.2%$60.00+1,370.6%+8.6%$59.41M$680K-0.999Earnings ReportHigh Trading VolumeDRRXDURECT1.8407 of 5 stars$1.90-0.5%N/A+55.4%$59.31M$2.03M-19.0080Short Interest ↓KALAKALA BIO4.087 of 5 stars$8.58+3.1%$13.00+51.5%+34.7%$58.42M$3.89M-1.2630 Related Companies and Tools Related Companies ANL Competitors GANX Competitors CVM Competitors HOWL Competitors IZTC Competitors ADVM Competitors INKT Competitors UNCY Competitors DRRX Competitors KALA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLRX) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access